Search Results - "Pierce, Kristen J."

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors by INFANTE, Jeffrey R, ROSS CAMIDGE, D, MARTIN SHREEVE, S, BURRIS, Howard A, SIU, Lillian L, MILESHKIN, Linda R, CHEN, Eric X, HICKS, Rodney J, RISCHIN, Danny, FINGERT, Howard, PIERCE, Kristen J, HUIPING XU, GREGORY ROBERTS, W

“…PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK). The objectives of this study were to identify the recommended phase II dose (RP2D) and assess…”
Get full text

Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers by Lewis, Nancy L, Lewis, Lionel D, Eder, Joseph P, Reddy, Nandi J, Guo, Feng, Pierce, Kristen J, Olszanski, Anthony J, Cohen, Roger B

“…This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD) of an oral platelet-derived growth…”
Get full text

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer by Shapiro, Geoffrey I, Bell-McGuinn, Katherine M, Molina, Julian R, Bendell, Johanna, Spicer, James, Kwak, Eunice L, Pandya, Susan S, Millham, Robert, Borzillo, Gary, Pierce, Kristen J, Han, Lixin, Houk, Brett E, Gallo, Jorge D, Alsina, Maria, Braña, Irene, Tabernero, Josep

“…To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I…”
Get full text

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors by Jones, Suzanne F., Siu, Lillian L., Bendell, Johanna C., Cleary, James M., Razak, Albiruni R. A., Infante, Jeffrey R., Pandya, Shuchi S., Bedard, Philippe L., Pierce, Kristen J., Houk, Brett, Roberts, W. Gregory, Shreeve, S. Martin, Shapiro, Geoffrey I.

“…Summary Objective VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine…”
Get full text

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer by Curigliano, Giuseppe, Shapiro, Geoffrey I., Kristeleit, Rebecca S., Abdul Razak, Albiruni R., Leong, Stephen, Alsina, Maria, Giordano, Antonio, Gelmon, Karen A., Stringer-Reasor, Erica, Vaishampayan, Ulka N., Middleton, Mark, Olszanski, Anthony J., Rugo, Hope S., Kern, Kenneth A., Pathan, Nuzhat, Perea, Rachelle, Pierce, Kristen J., Mutka, Sarah C., Wainberg, Zev A.

“…Background This Phase 1b study (B2151002) evaluated the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with other anti-tumour agents in advanced…”
Get full text

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer by Wainberg, Zev A., Alsina, Maria, Soares, Heloisa P., Braña, Irene, Britten, Carolyn D., Del Conte, Gianluca, Ezeh, Patrick, Houk, Brett, Kern, Kenneth A., Leong, Stephen, Pathan, Nuzhat, Pierce, Kristen J., Siu, Lillian L., Vermette, Jennifer, Tabernero, Josep

“…Background This phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and gedatolisib (PF-05212384; arms…”
Get full text

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer by Curigliano, Giuseppe, Shapiro, Geoffrey I., Kristeleit, Rebecca S., Abdul Razak, Albiruni R., Leong, Stephen, Alsina, Maria, Giordano, Antonio, Gelmon, Karen A., Stringer-Reasor, Erica, Vaishampayan, Ulka N., Middleton, Mark, Olszanski, Anthony J., Rugo, Hope S., Kern, Kenneth A., Pathan, Nuzhat, Perea, Rachelle, Pierce, Kristen J., Mutka, Sarah C., Wainberg, Zev A.

Get full text

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia by Wang, Eunice S., Aplenc, Richard, Chirnomas, Deborah, Dugan, Michael, Fazal, Salman, Iyer, Swaminathan, Lin, Tara L., Nand, Sucha, Pierce, Kristen J., Shami, Paul J., Vermette, Jennifer J., Abboud, Camille N.

“…Gemtuzumab ozogamicin (GO) remained available to US clinicians through an open-label expanded-access protocol (NCT02312037) until GO was reapproved. Patients…”
Get full text

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours by Schöffski, Patrick, Jones, Suzanne F, Dumez, Herlinde, Infante, Jeffrey R, Van Mieghem, Elke, Fowst, Camilla, Gerletti, Paola, Xu, Huiping, Jakubczak, John L, English, Patricia A, Pierce, Kristen J, Burris, Howard A

“…Abstract This phase I study (ClinicalTrials.gov ID: NCT00424632 ) evaluated the safe dose, pharmacokinetics, and pharmacodynamics of the aurora kinase A and B…”
Get full text

A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsiv,e high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B by Shore, Neal D., Powles, Thomas, Bedke, Jens, Galsky, Matt D., Kopyltsov, Evgeny, Necchi, Andrea, Palou, Joan, Vermette, Jennifer J., Randall, Alison E., Pierce, Kristen J., Cesari, Rossano, Steinberg, Gary D.

“…TPS4614 Background: Bacillus Calmette-Guérin (BCG) therapy is the standard of care for high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral…”
Get full text

Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC) by Wesolowski, Robert, Pathan, Nuzhat, Zhu, Zhou, Stringer-Reasor, Erica Michelle, Han, Hyo S., Dees, Elizabeth Claire, Bardia, Aditya, Layman, Rachel M., Weise, Amy, Kabos, Peter, Lu, Janice M., Kern, Kenneth Alan, Pierce, Kristen J., Rugo, Hope S.

“…Abstract only 1052 Background: Endocrine therapy with a CDK4/6 inhibitor (CDKi) is standard of care (SOC) for patients (pts) with estrogen-receptor-positive…”
Get full text

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia by Wang, Eunice S., Aplenc, Richard, Chirnomas, Deborah, Dugan, Michael John, Fazal, Salman, Iyer, Swaminathan, Lin, Tara L, Nand, Sucha, Pierce, Kristen J, Shami, Paul J, Vermette, Jennifer J, Abboud, Camille N

“…Introduction: Gemtuzumab ozogamicin (GO; MylotargTM) is an antibody-drug conjugate composed of an anti-CD33 monoclonal antibody covalently linked to the potent…”
Get full text

Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009; NCT02684032) by Forero-Torres, Andres, Wesolowski, Robert, Bardia, Aditya, Jhangiani, Haresh S., Kabos, Peter, Dees, Elizabeth Claire, Kern, Kenneth Alan, Perea, Rachelle, Pierce, Kristen J., Rugo, Hope S.

“…Abstract only TPS1113 Background: Hormone receptor positive (HR+) disease is the most common subset of both early and late stage breast cancer (BC). The…”
Get full text

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009) by Forero-Torres, Andres, Han, Heather, Dees, Elizabeth Claire, Wesolowski, Robert, Bardia, Aditya, Kabos, Peter, Layman, Rachel M., Lu, Janice M., Kern, Kenneth Alan, Perea, Rachelle, Pierce, Kristen J., Houk, Brett, Pathan, Nuzhat, Rugo, Hope S.

“…Abstract only…”
Get full text

Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715) by Wainberg, Zev A., Brega, Nicoletta, Davis, Craig, Gollerkeri, Ashwin, Pierce, Kristen J., Suzuki, Mie, Perea, Rachelle

“…Abstract only…”
Get full text

Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib by Wainberg, Zev A., Shapiro, Geoffrey, Curigliano, Giuseppe, Kristeleit, Rebecca Sophie, Leong, Stephen, Alsina, Maria, Milella, Michele, Britten, Carolyn D., Gelmon, Karen A., Olszanski, Anthony J., Vaishampayan, Ulka N., Lopez-Martin, Jose A., Kern, Kenneth Alan, Pierce, Kristen J., Perea, Rachelle, Houk, Brett, Pathan, Nuzhat, Razak, Albiruni R.

“…Abstract only…”
Get full text

Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents by Wainberg, Zev A., Shapiro, Geoffrey, Curigliano, Giuseppe, Leong, Stephen, Kristeleit, Rebecca Sophie, Alsina Maqueda, Maria, Britten, Carolyn D., Milella, Michele, Middleton, Mark R., Olszanski, Anthony J., Vaishampayan, Ulka N., Lopez-Martin, Jose A., Gelmon, Karen A., Brega, Nicoletta, Pierce, Kristen J., Perea, Rachelle, Houk, Brett Edward, Pathan, Nuzhat, Gollerkeri, Ashwin, Razak, Albiruni R. A.

“…Abstract only…”
Get full text